Costa Rican Tarrazú Coffee (Coffea arabica 'Costa Rican Tarrazú')

Costa Rican Tarrazú Coffee (Coffea arabica) is a high-altitude arabica cultivar containing concentrated chlorogenic acids (36–55 mg/g) and melanoidins that act as antioxidants and modulate glucose metabolism. Its primary bioactive mechanism involves inhibition of alpha-glucosidase and free-radical scavenging, though no clinical trials have been conducted specifically on this cultivar.

Origin & History

Costa Rican Tarrazú Coffee is a premium Coffea arabica cultivar grown at 3,000-6,000 feet elevation in the volcanic soils of west-central Costa Rica's Tarrazú region. The beans are wet-processed (washed), sun-dried, and typically medium to dark roasted, producing small, dense beans with bright acidity and citrus notes.

Historical & Cultural Context

Costa Rican Tarrazú Coffee has no documented traditional medicinal use in any traditional medicine systems. It is recognized primarily as a gourmet beverage crop valued for its sensory qualities including acidity, body, and flavor since cultivation began in the Talamanca Sierra region.

Health Benefits

• No clinical evidence exists specifically for Costa Rican Tarrazú Coffee - all benefits are theoretical based on general C. arabica studies
• May provide antioxidant effects from chlorogenic acids (36-55 mg/g) and melanoidins - evidence quality: preliminary (chemical analysis only)
• Contains caffeine (1.2-3.9 mg/g) for potential neurostimulant effects - evidence quality: not studied for this cultivar
• May support glucose and lipid metabolism through chlorogenic acid content - evidence quality: no Tarrazú-specific data
• Potential anti-inflammatory properties from phenolic compounds - evidence quality: theoretical only

How It Works

Chlorogenic acids in Tarrazú Coffee, particularly 5-caffeoylquinic acid, inhibit alpha-glucosidase and glucose-6-phosphatase enzymes in the intestine and liver, blunting postprandial blood glucose spikes. Caffeine (approximately 1.2–1.5% dry weight) antagonizes adenosine A1 and A2A receptors in the central nervous system, increasing dopamine and norepinephrine signaling to enhance alertness and thermogenesis. Melanoidins formed during roasting contribute additional antioxidant capacity by chelating transition metals and scavenging reactive oxygen species via their high-molecular-weight polymer structures.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted specifically on Costa Rican Tarrazú Coffee. Available research consists only of chemical characterizations of related C. arabica varieties without clinical trial references or PubMed PMIDs.

Clinical Summary

No clinical trials have been conducted specifically on Costa Rican Tarrazú Coffee as a distinct cultivar; all evidence is extrapolated from general Coffea arabica studies. Meta-analyses of regular arabica coffee consumption (3–5 cups/day) in large cohort studies (n > 100,000) associate intake with reduced risk of type 2 diabetes and liver disease, though causality is not established. Chlorogenic acid isolate trials in small human studies (n = 20–40) show modest fasting glucose reductions of 5–10% at doses of 400–600 mg/day. Evidence for Tarrazú-specific health outcomes remains at the chemical-analysis level only, and no dose-response data exist for this cultivar.

Nutritional Profile

Per 100g dry roasted coffee beans: Calories ~330 kcal, Protein ~13-15g (incomplete protein, limited bioavailability due to cell wall matrix), Total Carbohydrates ~28-32g (primarily polysaccharides; sucrose largely degraded during roasting to ~1-3g residual), Dietary Fiber ~23-25g (predominantly mannans and arabinogalactans from cell wall), Fat ~15-17g (primarily triglycerides and diterpenes cafestol ~3.5mg/g and kahweol ~2.8mg/g — concentrations vary by brew method; filtered coffee retains <0.1mg/g of each). Per standard 200ml brewed cup (using ~10g grounds): Caffeine 80-120mg (1.2-3.9mg/g dry bean basis; Tarrazú altitude >1500m MASL correlates with higher caffeine expression ~1.8-2.4mg/g typical), Chlorogenic acids (CGA) 70-200mg/cup (predominantly 5-caffeoylquinic acid; green bean content 36-55mg/g substantially reduced 50-70% by medium-dark roasting typical of Tarrazú processing), Trigonelline 10-30mg/cup (partially converted to niacin/nicotinic acid during roasting, yielding ~1-3mg niacin equivalent per cup), Melanoidins 200-400mg/cup (high-molecular-weight Maillard products with proposed prebiotic and antioxidant properties; concentration increases with roast degree), Potassium 80-115mg/cup (most abundant mineral; good bioavailability), Magnesium 7-10mg/cup, Niacin (B3) 0.5-2mg/cup (roasting-derived from trigonelline degradation), Riboflavin (B2) trace <0.05mg/cup. Tarrazú-specific profile notes: volcanic Andisol soils with high organic matter (>10%) and altitude-driven slow cherry maturation contribute to elevated sucrose in green beans (~8-9g/100g vs. ~6-7g lowland arabica), which translates to enhanced caramelization compounds and acidity (malic and citric acids ~3-5mg/cup combined) post-roast. Washed/wet processing standard to region removes mucilage, reducing fermentation-derived organic acid variability. Bioavailability: CGAs exhibit 30-60% jejunal absorption; colonic microbiota metabolize remainder to phenylpropionic acids. Diterpenes cafestol/kahweol bioaccessibility is brew-method dependent — espresso retains moderate levels (~0.5-1mg/shot), while paper-filtered drip (common export preparation) strips >90% of diterpenes.

Preparation & Dosage

No clinically studied dosage ranges exist for Costa Rican Tarrazú Coffee. Chemical analyses show chlorogenic acid content of 36-55 mg/g and caffeine 1.2-1.8 mg/g in green beans, with caffeine increasing to 2.5-3.9 mg/g after roasting. No standardization protocols or therapeutic doses have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, L-theanine, rhodiola, ashwagandha, milk thistle

Safety & Interactions

Caffeine content (approximately 80–100 mg per 8 oz serving) can cause insomnia, tachycardia, anxiety, and hypertension at high intakes, particularly in caffeine-sensitive individuals. Chlorogenic acids may enhance the hypoglycemic effect of metformin and insulin, requiring blood glucose monitoring in diabetic patients. Tarrazú Coffee is contraindicated in individuals with severe anxiety disorders, uncontrolled hypertension, or arrhythmias, and caffeine crosses the placenta, making consumption during pregnancy inadvisable above 200 mg/day per most obstetric guidelines. Concurrent use with MAO inhibitors, stimulants, or fluoroquinolone antibiotics (which inhibit caffeine metabolism via CYP1A2) can potentiate adverse effects.